HK inno.N and Il-Dong Pharmaceutical are launching new formulations of hyperlipidemia combination drugs designed to improve patient convenience and expand treatment options.
According to the pharmaceutical and biotech industry on the 22nd, HK inno.N plans to launch its dyslipidemia treatment "Zepito Tablet 10/5mg" in March. Zepito is a combination drug that combines ezetimibe, which blocks cholesterol absorption in the small intestine, with atorvastatin, which inhibits cholesterol production in the liver, to improve blood lipid levels.
Zepito Tablet 10/5mg, containing ezetimibe 10mg and atorvastatin 5mg, is a low-dose statin-based combination drug that can reduce concerns about statin-related side effects while still delivering improvements in low-density lipoprotein cholesterol (LDL-C). The product features bottle packaging to enhance medication and dispensing convenience.
Il-Dong Pharmaceutical plans to launch its dyslipidemia treatment Pitacujet 1/10mg in April. This product is a combination drug containing ezetimibe and pitavastatin, an HMG-CoA reductase inhibitor that lowers LDL cholesterol.
Pharmaceutical companies are successively launching hyperlipidemia combination drugs in response to the expanding market. According to UBIST, outpatient prescription sales of combination drugs including atorvastatin and ezetimibe grew from 582 billion won in 2021 to 728.6 billion won in 2022, 883.7 billion won in 2023, and 1.0508 trillion won in 2024, doubling over four years.
"Blockbuster drugs are emerging one after another in the hyperlipidemia combination drug market, with Hanmi Pharmaceutical's Rosuzet and Yuhan Corporation's Rosuvamibe each surpassing 200 billion won and 100 billion won in outpatient prescriptions, respectively," a pharmaceutical industry official said. "New types of combination drugs will continue to be launched going forward."